Search research articles
Contact Us
Filters
Showing results (331-340 of 410) with videos related to
Page
of 41
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2023
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
Susan Halabi, Qian Yang, Akash Roy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2009
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study
Daniel Y C Heng, Wanling Xie, Meredith M Regan, et al.
Frontiers in Oncology
|
January 22, 2025
Initial clinical experience with [<sup>177</sup>Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial
Aaron R Hansen, Stephan Probst, Jean-Mathieu Beauregard, et al.
European Journal of Radiology
|
July 12, 2026
Assessment of treatment response in recurrent medulloblastoma using craniospinal MRI
Juliane Hennenberg, Leo Hofer, Bence Nemeth, et al.
JAMA Oncology
|
September 17, 2020
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial
Srikala S Sridhar, Normand Blais, Ben Tran, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 3, 2023
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
K N Chi, S Sandhu, M R Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 2, 2016
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial
Daniel P Petrylak, Scott T Tagawa, Manish Kohli, et al.
JAMA Oncology
|
October 26, 2023
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial
Andreas Peyrl, Monika Chocholous, Magnus Sabel, et al.
Clinical Genitourinary Cancer
|
May 7, 2019
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205
Sebastien J Hotte, Kim N Chi, Anthony M Joshua, et al.
European Urology
|
May 27, 2020
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer
Cameron Herberts, Andrew J Murtha, Simon Fu, et al.
Page
of 41
Search research articles
Search
Showing results (331-340 of 410) with videos related to
Sort By:
Page
of 41
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2023
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
Susan Halabi, Qian Yang, Akash Roy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2009
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study
Daniel Y C Heng, Wanling Xie, Meredith M Regan, et al.
Frontiers in Oncology
|
January 22, 2025
Initial clinical experience with [<sup>177</sup>Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial
Aaron R Hansen, Stephan Probst, Jean-Mathieu Beauregard, et al.
European Journal of Radiology
|
July 12, 2026
Assessment of treatment response in recurrent medulloblastoma using craniospinal MRI
Juliane Hennenberg, Leo Hofer, Bence Nemeth, et al.
JAMA Oncology
|
September 17, 2020
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial
Srikala S Sridhar, Normand Blais, Ben Tran, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 3, 2023
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
K N Chi, S Sandhu, M R Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 2, 2016
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial
Daniel P Petrylak, Scott T Tagawa, Manish Kohli, et al.
JAMA Oncology
|
October 26, 2023
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial
Andreas Peyrl, Monika Chocholous, Magnus Sabel, et al.
Clinical Genitourinary Cancer
|
May 7, 2019
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205
Sebastien J Hotte, Kim N Chi, Anthony M Joshua, et al.
European Urology
|
May 27, 2020
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer
Cameron Herberts, Andrew J Murtha, Simon Fu, et al.
Page
of 41